BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 34922269)

  • 1. Evaluation of DNA methylation in promoter regions of hTERT, TWIST1, VIM and NID2 genes in Moroccan bladder cancer patients.
    El Azzouzi M; El Ahanidi H; Hafidi Alaoui C; Chaoui I; Benbacer L; Tetou M; Hassan I; Bensaid M; Oukabli M; Ameur A; Al Bouzidi A; El Mzibri M; Attaleb M
    Cancer Genet; 2022 Jan; 260-261():41-45. PubMed ID: 34922269
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hypermethylation of TWIST1 and NID2 in tumor tissues and voided urine in urinary bladder cancer patients.
    Yegin Z; Gunes S; Buyukalpelli R
    DNA Cell Biol; 2013 Jul; 32(7):386-92. PubMed ID: 23682613
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnosis of bladder cancer recurrence based on urinary levels of EOMES, HOXA9, POU4F2, TWIST1, VIM, and ZNF154 hypermethylation.
    Reinert T; Borre M; Christiansen A; Hermann GG; Ørntoft TF; Dyrskjøt L
    PLoS One; 2012; 7(10):e46297. PubMed ID: 23056278
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multi-institutional external validation of urinary TWIST1 and NID2 methylation as a diagnostic test for bladder cancer.
    Fantony JJ; Abern MR; Gopalakrishna A; Owusu R; Jack Tay K; Lance RS; Inman BA
    Urol Oncol; 2015 Sep; 33(9):387.e1-6. PubMed ID: 26027762
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical performance and utility of a noninvasive urine-based methylation biomarker: TWIST1/Vimentin to detect urothelial carcinoma of the bladder.
    Zhang C; Xu X; Wang T; Lu Y; Lu Z; Wang T; Pan Z
    Sci Rep; 2024 Apr; 14(1):7941. PubMed ID: 38575639
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification and validation of the methylated TWIST1 and NID2 genes through real-time methylation-specific polymerase chain reaction assays for the noninvasive detection of primary bladder cancer in urine samples.
    Renard I; Joniau S; van Cleynenbreugel B; Collette C; Naômé C; Vlassenbroeck I; Nicolas H; de Leval J; Straub J; Van Criekinge W; Hamida W; Hellel M; Thomas A; de Leval L; Bierau K; Waltregny D
    Eur Urol; 2010 Jul; 58(1):96-104. PubMed ID: 19674832
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Urinary NID2 and TWIST1 methylation to augment conventional urine cytology for the detection of bladder cancer.
    Fantony JJ; Longo TA; Gopalakrishna A; Owusu R; Lance RS; Foo WC; Inman BA; Abern MR
    Cancer Biomark; 2017; 18(4):381-387. PubMed ID: 28106542
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Promoter hypermethylation of the 14-3-3 sigma, SYK and CAGE-1 genes is related to the various phenotypes of urinary bladder carcinomas and associated with progression of transitional cell carcinomas.
    Kunze E; Wendt M; Schlott T
    Int J Mol Med; 2006 Oct; 18(4):547-57. PubMed ID: 16964403
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A DNA hypermethylation profile reveals new potential biomarkers for the evaluation of prognosis in urothelial bladder cancer.
    López JI; Angulo JC; Martín A; Sánchez-Chapado M; González-Corpas A; Colás B; Ropero S
    APMIS; 2017 Sep; 125(9):787-796. PubMed ID: 28586118
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Detection of bladder cancer in voided urine samples].
    Thomas A; Renard I; Waltregny D
    Rev Med Liege; 2009; 64 Spec No():9-14. PubMed ID: 20085009
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Promoter hypermethylation in tumour suppressor genes shows association with stage, grade and invasiveness of bladder cancer.
    Jarmalaite S; Jankevicius F; Kurgonaite K; Suziedelis K; Mutanen P; Husgafvel-Pursiainen K
    Oncology; 2008; 75(3-4):145-51. PubMed ID: 18824877
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A noninvasive urine-based methylation biomarker panel to detect bladder cancer and discriminate cancer grade.
    Hermanns T; Savio AJ; Olkhov-Mitsel E; Mari A; Wettstein MS; Saba K; Bhindi B; Kuk C; Poyet C; Wild PJ; Noon A; Bashir S; Juvet T; Rendon RA; Waltregny D; van der Kwast T; Finelli A; Kulkarni GS; Fleshner NE; Lo K; Bapat B; Zlotta AR
    Urol Oncol; 2020 Jun; 38(6):603.e1-603.e7. PubMed ID: 32081560
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical performance and utility of a DNA methylation urine test for bladder cancer.
    Abern MR; Owusu R; Inman BA
    Urol Oncol; 2014 Jan; 32(1):51.e21-6. PubMed ID: 24360662
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TWIST1 promoter methylation is associated with prognosis in tonsillar squamous cell carcinoma.
    Kwon MJ; Kwon JH; Nam ES; Shin HS; Lee DJ; Kim JH; Rho YS; Sung CO; Lee WJ; Cho SJ
    Hum Pathol; 2013 Sep; 44(9):1722-9. PubMed ID: 23664538
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regularly methylated novel pro-apoptotic genes associated with recurrence in transitional cell carcinoma of the bladder.
    Christoph F; Weikert S; Kempkensteffen C; Krause H; Schostak M; Miller K; Schrader M
    Int J Cancer; 2006 Sep; 119(6):1396-402. PubMed ID: 16642478
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Promoter hypermethylation of CDH13, DAPK1 and TWIST1 genes in precancerous and cancerous lesions of the uterine cervix.
    Missaoui N; Hmissa S; Trabelsi A; Traoré C; Mokni M; Dante R; Frappart L
    Pathol Res Pract; 2011 Jan; 207(1):37-42. PubMed ID: 21129853
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TRIM29 suppresses TWIST1 and invasive breast cancer behavior.
    Ai L; Kim WJ; Alpay M; Tang M; Pardo CE; Hatakeyama S; May WS; Kladde MP; Heldermon CD; Siegel EM; Brown KD
    Cancer Res; 2014 Sep; 74(17):4875-87. PubMed ID: 24950909
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Methylation of HOXA9 and ISL1 Predicts Patient Outcome in High-Grade Non-Invasive Bladder Cancer.
    Kitchen MO; Bryan RT; Haworth KE; Emes RD; Luscombe C; Gommersall L; Cheng KK; Zeegers MP; James ND; Devall AJ; Fryer AA; Farrell WE
    PLoS One; 2015; 10(9):e0137003. PubMed ID: 26332997
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NID2 and HOXA9 promoter hypermethylation as biomarkers for prevention and early detection in oral cavity squamous cell carcinoma tissues and saliva.
    Guerrero-Preston R; Soudry E; Acero J; Orera M; Moreno-López L; Macía-Colón G; Jaffe A; Berdasco M; Ili-Gangas C; Brebi-Mieville P; Fu Y; Engstrom C; Irizarry RA; Esteller M; Westra W; Koch W; Califano J; Sidransky D
    Cancer Prev Res (Phila); 2011 Jul; 4(7):1061-72. PubMed ID: 21558411
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Promoter methylation of DNA damage repair (DDR) genes in human tumor entities:
    Mijnes J; Veeck J; Gaisa NT; Burghardt E; de Ruijter TC; Gostek S; Dahl E; Pfister D; Schmid SC; Knüchel R; Rose M
    Clin Epigenetics; 2018; 10():15. PubMed ID: 29445424
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.